Icon

SIMBRINZA (nda204251)- (0.2%;1%)

BRIMONIDINE TARTRATE; BRINZOLAMIDE ALCON LABS INC
0.2%;1%
Yes Yes
2030-Oct-30 Expired
None None
None No
SIMBRINZA™ is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
0 1 0
Total Other Developers 11
Drugs with Suitability No
0.2%;1% ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.